In women with menorrhagia and prolonged bleeding time, desmopressin alone significantly reduced blood loss during the two treatment days versus placebo.
In plain wordsIn women with menorrhagia and prolonged bleeding time, desmopressin alone significantly reduced blood loss during treatment compared with placebo.
- Peptide
- Desmopressin
- Outcome
- DecreaseBlood loss during two treatment days
- Study
n: not reported in source
- Comparator
- Placebo
- Outcome group
- Bleeding · Reproductive and sexual health
- Studied dose
- 300 microg · nasal inhalation · 2 daysAs given in this study (human).
Source sentences
When analyzing the blood loss during the two treatment days, there was a significant reduction in blood loss for the 2 days with desmopressin alone versus placebo.
3 context sentences(design, population, supporting numbers)
The objective of this study was to investigate the efficacy and safety of desmopressin (1-desamino-8-D-arginine vasopressin) compared with placebo in the reduction of menstrual blood loss in women with menorrhagia and prolonged bleeding time, but without common coagulation factor deficiencies.
We performed a randomized, double-blind, cross-over study using 300 microg desmopressin nasal inhalation or placebo treatment in one of the two first treatment cycles.
Desmopressin was given only for the 2 days during which the bleeding had been at a maximum in the previous baseline cycle.